Hideki Tomioka
Chief Scientific Officer - Research & Development FunPep
Hideki Tomioka, Ph.D. is a Director of the Board at FunPep Co., Ltd.. He graduated from Graduate School of Pharmaceutical Sciences, Tokyo University of Science in March 1997. He was employed in Ono Pharmaceutical Co., Ltd. from 1997 to 2005. He worked as a researcher at AnGes MG, Inc. from 2005 to 2015. He received his Ph.D from Graduate School of Medicine, Osaka University in March 2014. He joined FunPep Co., Ltd.in 2015. His research interests the functional peptides. He leads the active immunotherapy project at FunPep Co., Ltd.. There is a unique technology to our active immunotherapy candidates as they have a selectivity of the immune response.
Seminars
Thursday 30th April 2026
Active Immunotherapy Using Universal Epitopes
1:30 pm
- Peptide vaccine technology involves prolonged suppression due to the production of anti-endogenous target protein antibody
- Peptide vaccines consist of highly immunogenic helper T cell epitope (AJP001) and B cell epitope originated from target protein
- Sharing the usefulness of antibody-inducing peptides based on non-clinical and clinical trial data of developed compounds
NEW COMPANY
